Search

everythinglearnresearchcommunity

for

Search:↓

Lymphoid-specific helicase (Lsh) is crucial for skin growth, change, and healing after injury.

A young boy's uncombable hair is due to a rare genetic condition that usually improves over time.

The Japan Society of Clinical Hair Restoration (JSCHR) focuses on improving hair restoration techniques in Japan.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

Short scalp flaps are easier but not good for severe baldness; Juri flaps are complex but better for density and coverage.

Machine learning can predict how well patients with alopecia areata will respond to certain treatments.

Buschke-Ollendorff syndrome is a rare genetic disorder causing skin and bone changes, with some cases also showing ADHD or developmental delays.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Buserelin safely and effectively suppresses early puberty, potentially improving final height.

Thorough clinical examination is crucial for diagnosing unusual alopecia.

Sinseon-yukza-hwan shows strong antioxidant potential for hair and scalp cosmetics.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.

Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.

TBX5 gene influences feathered feet in Guangxi chickens by affecting cell growth and movement.

The document's conclusion cannot be summarized because the content is not available.

Splitting one hair follicle into two can help regrow hair with a 50% to 70% success rate, useful when donor hair is limited.

Researchers found a new gene variant linked to a rare bone disease, which doesn't always cause symptoms in carriers.

Congenital triangular alopecia is more common than thought and some treatments can be beneficial for appearance concerns.

Abrocitinib may effectively treat stubborn alopecia universalis.

Jojoba roots have unique properties that were previously unexplored.

AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.